Clinical Trial Detail

NCT ID NCT01876953
Title Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

acute myeloid leukemia

Therapies

Cytarabine + Dasatinib + Idarubicin

Age Groups: adult

No variant requirements are available.